This 24-hour trial randomized 476 cancer patients at 29 centers to 1. 8 or 2.4 mg/kg IV DM or G (3 mg) 30 minutes prior to ≥ 80 mg/m 2 IV cisplatin CT. Patients were stratified using gender and previous CT to four groups: male naive and non-naive and female naive and non-naive. Efficacy was measured using complete response (CR: 0 emetic episodes [EE] and no rescue medication [RM]); CR + major response (CMR: 12 EE and no RM); ratings of nausea and satisfaction by patients on a 100 mm visual analog scale (VAS); and physician assessment of nausea severity and global efficacy on a discrete scale (DS: none, slight, good, excellent). CR rates were 54%, 47%, and 48%, respectively, for DM 1.8 and 2.4 mg/kg and G. CR rates for both DM doses were statistically equivalent to G and pairwise comparisons of CR rates between DM 1.8 mg/kg and G ( P = 0893) and between the two DM doses ( P = 0602) were not statistically significant. Equivalence between treatments was further confirmed by CMR, by median time to first EE/RM, by patient VAS assessments, by the rigorous CR + no nausea (